Immunohistochemistry and double immunofluorescence staining

YJ Ying Jin
YL Yao Liu
LX Lei Xu
JX Jie Xu
YX Yulian Xiong
YP Yazhi Peng
KD Ke Ding
SZ Shuang Zheng
NY Nan Yang
ZZ Zemei Zhang
LL Lin Li
LT Liguo Tan
HS HongXian Song
JF Jian Fu
ask Ask a question
Favorite

Immunohistochemistry was conducted as described previously [13, 20]. Mouse tissues were fixed in 60% methanol and 10% acetic acid in H2O and paraffin embedded. Following deparaffinization and rehydration, tissue sections were treated with 3% hydrogen peroxide solution for 20 min to block endogenous peroxides activity. Antigen retrieval was carried out by treatment of the slides with 10 mM sodium citrate buffer (pH 6.0) or EDTA (pH 9.0) by microwaving for 10 min. The samples were blocked with 5% FBS in 0.1% PBS/BSA and incubated with primary antibody overnight at 4 °C. The standard streptavidin–biotin linked horseradish peroxidase technique was applied with 3,30-diaminobenzidine tetrahydrochloride for the development of peroxidase activity. The sections were counterstained with hematoxylin.

Double immunofluorescence staining was performed as described previously [13]. Primary antibodies used include the following: anti-α-smooth actin (Santa Cruz Biotechnology, sc-130616), anti-MCP1 (R&D systems, 479-JE-010; Novus Biologicals, NBP2-22115), anti-active caspase 1 (Invitrogen, AAC504N), anti-NLRP3 (AdipoGen, AG-20B-0014), anti-interleukin-1β (R&D systems, AF-401-NA), anti-LC3 (Sigma, L8918), anti-p62 (MBL, PM045), anti-Mac3 (BD Pharmingen, #550292), anti-ICAM1 (R&D systems, AF796) and anti-cleaved caspase 3 (Cell Signaling Technology, #9661). Images were captured through a Nikon upright microscope with an objective set to ×4 or ×20 magnification, quantified using CellSens Standard software, and expressed as percent of plaque area (%) = (staining positive area/plaque area) × 100%.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A